Navigation Links
WuXi PharmaTech Appoints Wei-Min Chang as Vice President of Operations and General Manager of SynTheAll Manufacturing Facility, Eric Gu as Vice President of Business Development for Manufacturing Services
Date:6/21/2009

SHANGHAI, June 21 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device research and development outsourcing company with operations in China and the United States, today announced that Wei-Min Chang has been appointed Vice President of Operations and General Manager of the company's SynTheAll (STA) manufacturing facility, located in the Jinshan chemical industry zone of Shanghai. Mr. Chang will report to Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Dr. Eric Gu, former Vice President of Operations and General Manager of STA, has been appointed Vice President of Business Development for Manufacturing Services, reporting to Dr. Suhan Tang, Chief Manufacturing Officer.

The Company's SynTheAll facility manufactures active pharmaceutical ingredients (APIs) and advanced intermediates for our customers' use in preclinical and clinical trials. The company recently completed construction of an expanded facility, known as SynTheAll Phase 2, to produce advanced intermediates and APIs for late-stage clinical trials and commercial supplies. This new facility is expected to open in stages, beginning in late 2009.

Prior to joining WuXi, Mr. Chang worked at Eastbound Synopharma (HK) Holding Co. as Vice President of Chemical Development, responsible for research and development, small-scale manufacturing, quality control/quality assurance, regulatory affairs and other general administrative functions at Eastbound Shanghai Institute. From 1999 to 2006, he worked for Taiwan Biotech as the company's head of U.S. operations and as Vice President of R&D/Quality/Regulat
'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. WuXi PharmaTech to Present at Third Annual Jefferies Healthcare Conference
2. WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release
3. Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA
4. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results
5. The Fitzsimons Redevelopment Authority Selects Pharmatech Oncology as Preferred Vendor
6. Quest PharmaTech Announces Strategic Alliance with IntelligentNano to Develop Nanotechnology-Based Next Generation SL052
7. Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors
8. Quest PharmaTech Announces a Review of Strategic Alternatives to Enhance Shareholder Value
9. WuXi PharmaTech to Present at 27th Annual J.P. Morgan Healthcare Conference
10. Pharmatech 2.0: Introducing Pharmatech Oncology
11. WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)...  Decision Resources Group finds that the vascular access device market ... India and China ... to the size of the United States ... much faster growth as a result of strong economic expansion, improving ... findings from Decision Resources Group,s coverage of the BRIC vascular access ...
(Date:8/20/2014)... Not long ago, it was more ... performed late in the development cycle – even after ... trends suggest that, like many things GxP, expectations for ... years, multiple drug sponsors have been required by authorities ... during phase I/II. It’s not only clinical trial material ...
(Date:8/20/2014)... August 20, 2014 WriteResult®, a leading ... that it has expanded its myPROpad™ ePRO tablet with ... one of the most widely used and well-respected ... health status. The EQ-5D is used during clinical trials ... measure that can be used to demonstrate Health-Related Quality ...
(Date:8/19/2014)... Md. (PRWEB) August 19, 2014 ... liquid chromatography systems, Prominence-i and Nexera-i, adding to ... systems. Combining excellent functionality, an intuitive operating environment, ... and a more efficient workflow for conventional to ... feature innovative, intuitive and intelligent design so users ...
Breaking Biology Technology:BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2EQ-5D™ Assessment Now Available for iPad 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3
... 29 /PRNewswire-Asia/ -- RainEarth Inc.,(OTC Bulletin Board: RNER; "the ... and Earth Technology Development Corp. Ltd.,("China RainEarth") attended the ... , A good marketing strategy ... products. In the forum, participants explored various marketing,strategies and ...
... Calif., June 29 Kornberg Associates | Architects ( ... to design a new Cognitive & Neurobiological Imaging Center. ... The firm has worked with Stanford University since ... years, one of which is the two-story, 32,000 square-foot office ...
... Hutchinson Cancer Research Center board of trustees today announced that ... in June 2010. Hartwell, a recipient of the 2001 Nobel ... of the Hutchinson Center since 1997. , , ... of the Center for 12 years. It,s time for new ...
Cached Biology Technology:RainEarth (RNER) Continues to Expand its Marketing Force in China 2RainEarth (RNER) Continues to Expand its Marketing Force in China 3Kornberg Associates Architects Selected to Develop Design for New Stanford University Imaging Center 2Nobel Laureate Lee Hartwell to Retire as President and Director of Fred Hutchinson Cancer Research Center in 2010 2
(Date:8/20/2014)... Using population-based screening outcomes of approximately 3 million infants, ... researchers at the University of Massachusetts Medical School, have ... can be successfully implemented across public health newborn screening ... the Aug. 20 issue of the Journal of ... the rate of SCID in newborns is higher than ...
(Date:8/20/2014)... National Institutes of Health has awarded the Oklahoma Medical ... its research on anthrax and the bacteria,s effects on ... Coggeshall, Ph.D., and his colleagues have studied the human ... Cooperative Centers for Human Immunology. The original funding came ... on the heels of the terrorist attacks of Sept. ...
(Date:8/20/2014)... suffered concussions ready to return to action? A new ... athletes who head back on the field with medical ... their abilities to simultaneously walk and do simple mental ... their balance and/or altered walking speed, was found in ... returned to activity in less than a month. Seven ...
Breaking Biology News(10 mins):Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3$14.5 million grant awarded to continue anthrax studies 2Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... rearrangement hotspots has its most recent addition in a ... of California San Diego. The study, published on ... are indeed rearrangement hotspots in the human genome. ... for analyzing complex rearrangements (including transpositions) which demonstrates that ...
... TEMPE, Ariz. -- Anyone who has thrown a backyard barbecue ... than buns eight hot dogs per pack versus 10 ... weenie roasts are hot-dog limited the extra buns are ... limiting factors are a cornerstone of natural ecology, where phosphorus ...
... years, researchers have suspected there must be a natural ... body and could be harnessed to develop more effective ... Currently, drugs that lower sodium levels all have serious ... at Cornell and the Boyce Thompson Institute for Plant ...
Cached Biology News:At the root of nutrient limitation, ecosystems are not as different as they seem 2At the root of nutrient limitation, ecosystems are not as different as they seem 3Researchers' discovery may lead to hypertension treatment 2
Goat polyclonal to HSPC150 ( Abpromise for all tested applications). entrezGeneID: 29089...
Oct 2 Immunogen: Full length human protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Mouse monoclonal [3B6] to HSV1 + HSV2 ICP5 Major Capsid Protein ( Abpromise for all tested applications)....
Mouse monoclonal [2Q2147] to Aequorin ( Abpromise for all tested applications)....
Biology Products: